Milestone Scientific Highlights Growing Clinical Adoption and Expanding Physician Acceptance of CompuFlo® Across Epidural, Neuromodulation, and Interventional Pain Procedures

Strong clinical data, but no financials—investors get validation, not a business case.

What the company is saying

Milestone Scientific Inc. is positioning itself as a leader in innovative injection technologies, emphasizing the clinical validation and growing adoption of its CompuFlo® Epidural System. The company wants investors to believe that its technology is gaining significant traction in the medical community, citing a new peer-reviewed study from the University of Texas Medical Branch (UTMB) as a key milestone. The announcement frames CompuFlo as a breakthrough in procedural safety and precision, highlighting a 91% reduction in the odds of complications during spinal cord stimulator (SCS) implantation procedures. The language is assertive and optimistic, repeatedly referencing 'continued growth,' 'expanding clinical acceptance,' and 'broad and growing range' of applications, but it does not provide hard numbers on sales, revenue, or adoption rates. The press release foregrounds the clinical study and the number of institutions (over 40) that have evaluated or used CompuFlo, while omitting any discussion of financial performance, commercial contracts, or regulatory hurdles. Management’s tone is confident, projecting a sense of momentum and inevitability, but the communication style is typical of early-stage medtech—heavy on promise, light on quantifiable business outcomes. Notably, Dr. Dawood Sayed, a professor and vice chairman of a major pain and neuroscience society, is both a study author and a board member at Milestone, lending clinical credibility but also raising questions about independence. This narrative fits a classic medtech investor relations strategy: use clinical validation as a proxy for commercial potential, especially in the absence of financial traction. Compared to prior communications (which are not available for review), there is no evidence of a shift in messaging, but the focus remains squarely on clinical rather than commercial milestones.

What the data suggests

The only concrete numbers disclosed are a 91% reduction in the odds of composite complications (including CSF leak, epidural blood patch, and postoperative radiculopathy) in SCS procedures using CompuFlo, and the fact that the technology has been evaluated or utilized at more than 40 institutions worldwide. There are no period-over-period adoption metrics, revenue figures, or sales data provided, making it impossible to assess financial trajectory or commercial momentum. The gap between the company’s claims of 'continued growth' and 'expanding acceptance' and the actual data is significant: while the clinical outcome is impressive, there is no evidence of how this translates into market share, sales, or profitability. No prior targets or guidance are referenced, so it is unclear whether the company is meeting, exceeding, or missing its own benchmarks. The quality of financial disclosure is extremely poor—key metrics such as revenue, gross margin, cash burn, or even unit sales are entirely absent. An independent analyst, looking only at the numbers, would conclude that the technology is clinically promising but that the business case is unproven and unquantified. The announcement is best described as a clinical validation update, not a financial or commercial progress report.

Analysis

The announcement uses positive language to highlight clinical adoption and research outcomes for the CompuFlo® Epidural System, but provides limited measurable evidence beyond a single clinical study and a count of institutions. While the 91% reduction in complications is a strong data point, most other claims—such as 'continued growth,' 'expanding clinical acceptance,' and improved procedural outcomes—are not quantified or supported by new numerical data. The forward-looking statements about business plans, revenues, and regulatory approvals are generic and not backed by disclosed milestones or commitments. There is no mention of capital outlay or financial results, and the timeline for broader adoption or financial impact is not specified. The gap between narrative and evidence is moderate: the announcement leans on positive framing and broad claims, but only a subset is substantiated.

Risk flags

• ●Lack of financial disclosure: The announcement provides no revenue, profit, cash flow, or sales data, making it impossible for investors to assess the company’s financial health or trajectory. This is a major red flag for anyone considering an investment based on business fundamentals.
• ●Overreliance on clinical validation: While the 91% reduction in complications is impressive, the company conflates clinical success with commercial success. Many medtech products with strong clinical data have failed to achieve meaningful market penetration or profitability.
• ●Forward-looking statements dominate: The majority of business claims are forward-looking, referencing expected revenues, regulatory approvals, and future success without any supporting detail or binding commitments. This pattern is typical of early-stage or pre-commercial companies and signals high execution risk.
• ●No evidence of commercial traction: Despite claims of 'continued growth' and 'expanding acceptance,' there are no period-over-period adoption metrics, signed contracts, or customer testimonials. The gap between narrative and evidence suggests that commercial traction may be limited or nascent.
• ●Potential conflict of interest: Dr. Dawood Sayed, a prominent clinician and board member, is cited as both a study author and a company insider. While his involvement lends credibility, it also raises questions about the independence of the research and the objectivity of the claims.
• ●Unclear regulatory pathway: The announcement references regulatory approvals as a future milestone but provides no detail on current status, timelines, or hurdles. Regulatory risk remains unquantified and could delay or derail commercialization.
• ●No discussion of capital requirements: There is no mention of the company’s cash position, funding needs, or capital intensity. Investors have no visibility into whether the company can fund its business plan through to commercial success.
• ●Absence of competitive context: The announcement does not address competing technologies, market size, or barriers to adoption, leaving investors in the dark about the company’s relative positioning and the challenges it may face in scaling up.

Bottom line

For investors, this announcement is a clear signal that Milestone Scientific’s CompuFlo technology is clinically validated for a specific use case, but it offers no evidence of commercial momentum or financial viability. The 91% reduction in complications is a strong clinical outcome, but without sales data, revenue figures, or adoption metrics, it is impossible to gauge whether this is translating into business success. The involvement of a prominent clinician and board member adds credibility to the clinical claims, but does not guarantee commercial adoption or regulatory approval. To change this assessment, the company would need to disclose concrete financial results, period-over-period adoption rates, signed commercial agreements, or regulatory milestones achieved. Investors should watch for future announcements that include revenue growth, new customer wins, or regulatory clearances as key signals of progress. At this stage, the information is worth monitoring but not acting on—there is validation of the technology, but not of the business. The single most important takeaway is that clinical promise does not equal commercial success; until Milestone provides hard financial evidence, the investment case remains speculative.

Announcement summary

Milestone Scientific Inc. announced continued growth in clinical adoption and physician acceptance of its CompuFlo® Epidural System, following new peer-reviewed research from the University of Texas Medical Branch. The study, published in Operative Neurosurgery, showed that CompuFlo-guided epidural access during spinal cord stimulator implantation procedures was associated with significantly lower complication rates compared to conventional techniques. The publication highlights expanding clinical acceptance of CompuFlo technology across a broad range of procedures requiring accurate epidural space identification. CompuFlo provides continuous real-time pressure sensing and audible feedback during needle advancement, improving procedural precision, safety, and physician confidence. The UTMB study found a 91% reduction in the odds of composite complications in SCS procedures with CompuFlo guidance. The technology has been evaluated or utilized across more than 40 universities, academic medical centers, and teaching hospitals worldwide. The announcement also contains forward-looking statements regarding Milestone's business plan, expected revenues, regulatory approvals, and future success.

Disagree with this article?